Overview

24-month Ticagrelor-based Dual-antiplatelet Therapy Versus Clopidogrel-based Dual-antiplatelet theRapy aftEr 12 Months of DrUg-eluting Stent Implantation in High isChEmic Risk Patients: P-REDUCE Trial

Status:
Not yet recruiting

Trial end date:
2026-06-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this prospective randomized clinical trial is to compare the clinical outcomes between aspirin with ticagrelor versus aspirin with clopidogrel in high ischemic risk patients beyond 12 months after percutaneous coronary intervention with drug-eluting stent implantation

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Yonsei University

Treatments:

Clopidogrel
Ticagrelor

Criteria

Inclusion Criteria:

1. Age ≥50 years old

2. History of drug-eluting stent implantation due to acute myocardial infarction 12 to 24
months ago

3. High-risk for ischemic events (at least one of the following) 1) Age >65 years old 2)
Medical treatments for diabetes mellitus 3) Multi-vessel coronary artery disease 4)
More than 2 episodes of myocardial infarction 5) Chronic kidney disease (stage III or
IV)

Exclusion Criteria:

1. Age ≥85 years old

2. Pregnant women or women with potential childbearing

3. Life expectancy < 1 year

4. Inability to understand or read the informed consent

5. Need for long-term anticoagulation therapy